A research team at the University of Córdoba’s Chemical Institute for Energy and the Environment (IQUEMA) has achieved a significant breakthrough in battery technology, developing a prototype that partially runs on hemoglobin, the oxygen-carrying protein found in red blood cells. This biocompatible innovation holds promise for applications ranging from extreme environments to implantable medical devices.
The newly developed battery utilizes hemoglobin as a catalyst to facilitate the oxygen reduction reaction, a key step in converting chemical energy into electricity. This approach offers several advantages over conventional lithium-ion batteries, including:
- Enhanced durability: The researchers were able to operate their prototype for nearly 30 days using a miniscule amount of hemoglobin, suggesting extended lifespans compared to traditional batteries.
- Extreme condition resilience: Unlike lithium-ion batteries, which can be compromised by heat and humidity, this novel design exhibits tolerance to such environmental factors, making it suitable for harsh settings.
- Biocompatibility: The use of haemoglobin, a naturally occurring biomolecule, opens doors for potential integration with implantable medical devices, such as pacemakers, offering longer lifespans and reduced health risks compared to current options.
While the research is still in its early stages, the potential impact of this technology is undeniable. Further development could lead to batteries that power life-saving medical devices for extended periods, operate reliably in challenging environments, and pave the way for a new era of biocompatible electronics.
It is crucial to mention that these batteries require oxygen to function and therefore wouldn’t be suitable for applications in space or other oxygen-depleted environments.
